PD-1/IL-2 Bispecific Antibody as Neoadjuvant Therapy for Early Recurrent Hepatocellular Carcinoma After Curative Hepatectomy
Clinical trial NCT07644208 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07644208
- Sponsor
- Shanghai Zhongshan Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-06-15
- Primary completion
- 2028-06-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.